227 results
424B3
ZVRA
Zevra Therapeutics Inc
10 Apr 24
Prospectus supplement
4:23pm
prospectus may contain and incorporate by reference, market data and industry statistics and forecasts that are based on independent industry publications … in Zevra Therapeutics, Inc.’s Annual Report (Form 10-K) for the years ended December 31, 2023 and 2022 have been audited by Ernst & Young LLP, independent
8-K
qkit16ptgwl2z9
28 Mar 24
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
4:35pm
8-K
EX-99.1
pxdcz0
28 Mar 24
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
4:35pm
8-K
EX-3.1
5zxou
28 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:29pm
8-K/A
EX-23.1
v8swyrrf6hvbx9mi
5 Feb 24
Financial Statements and Exhibits
12:00am
8-K/A
qmcfgky2p2 ppd
5 Feb 24
Financial Statements and Exhibits
12:00am
424B5
czafz13 jr7e6a
21 Nov 23
Prospectus supplement for primary offering
7:40pm
8-K
EX-4.1
5xi85jv 275ycvtp6
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
EX-99.2
bicjtn
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
EX-10.1
8zu rc00s6v06ef4f6
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am